Bristol-myers Squibb Compnay

Icagen, Inc.

Bristol Meyers Squibb Company

Yoon T Jeon

Peter T Cheng

Pratik Devasthale

James R Corte

Wu Yang

Hao Zhang

Yufeng Wang

Sean Chen

Mimi Lifen Quan

Donald J P Pinto

Heather J Finlay

John E Lloyd

Carl P Decicco

Joanne M Smallheer

Karen Anita Rossi

Zilun Hu

Tianan Fang

Leon M Smith, Ii

Lin Yan

Michael F Gross

Charles G Clark

Patrick Y S Lam

Serge Beaudoin

William R Ewing

James A Johnson

Paul Joseph Gilligan

Wei Wang

Michael J Orwat

Jennifer X Qiao

Tammy C Wang

Carol Hui Hu

Carl Thibeault

Indawati DeLucca

Donald Jp Pinto

Charles G Clarke

Donald JP Pinto

Leon M Ii Smith

Patrick YS Lam

Ii Leon M Smith

The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Macrocycles as factor xia inhibitors

Macrocycles as factor XIA inhibitors

Macrocycles as factor XIa inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Yreceptor and may be used as medicaments in the treatment and/or prophylaxis of thromboembolic disorders. 

[object Object]

The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Cyclic P1 linkers as factor XIa inhibitors

The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same. 

A compound of formula I wherein R, R, R, Rand Rare described herein.

Novel heterocyclo compounds useful as inhibitors of potassium channel function (especially inhibitors of the K1 subfamily of voltage gated Kchannels, especially inhibitors K1.5 which has been linked to the ultra-rapidly activating delayed rectifier Kcurrent I), methods of using such compounds in the prevention and treatment of arrhythmia and I-associated conditions, and pharmaceutical compositions containing such compounds.

Heterocyclo inhibitors of potassium channel function

Compounds are provided which have the structure wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R, R, R, R, R, R, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

Compounds are provided which have the structure wherein Q is C or N, Xis C or N, and R, R, R, R, R, R, Y, A, m, n, X, Xand Xare as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method

Growing community of inventors

Belle Meade, NJ, United States of America

Yoon T Jeon